iOmx doses first patient in pivotal phase 1 study
Study becomes the first-in-human clinical trial involving OMX-0407 in a specific patient group
Read Moreby John Pinching | Apr 4, 2023 | News | 0
Study becomes the first-in-human clinical trial involving OMX-0407 in a specific patient group
Read Moreby John Pinching | Mar 29, 2023 | News | 0
Dr Beatriz Goulao receives more than £500,000 to make trials more patient-focused
Read Moreby John Pinching | Mar 29, 2023 | News | 0
Company’s candidate NP137 combined with mFOLFIRINOX will be researched during vital trials
Read Moreby John Pinching | Mar 28, 2023 | News | 0
Clinical trial involves patients with liver cirrhosis and hepatic encephalopathy
Read Moreby John Pinching | Mar 24, 2023 | News | 0
The multi-centre international clinical trial will evaluate company’s Debio 0328 candidate
Read Moreby John Pinching | Mar 14, 2023 | News | 0
The clinical trial also involves paclitaxel in the treatment of metastatic breast cancer
Read Moreby John Pinching | Mar 10, 2023 | News | 0
Collaboration will concentrate on launching and running studies within medical dermatology
Read Moreby John Pinching | Jun 13, 2022 | News | 0
First-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer and renal cancer
Read Moreby John Pinching | May 18, 2022 | News | 0
Device delivers currents to the brain to restore activity usually lowered in depression patients
Read Moreby John Pinching | Mar 31, 2022 | News | 0
MTX652 has advanced through preclinical regulatory toxicology studies and is ready for a phase 1 trial
Read Moreby Lucy Parsons | Apr 15, 2021 | News | 0
British drugmaker has discontinued treatment with investigational drug in two cancer trials
Read Moreby Anna Smith | May 23, 2019 | News | 0
SCIB2 is to be administered using a new nanoparticle formulation in a planned Phase I/II clinical trial.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479